✦ LIBER ✦

Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial

✍ Scribed by Antonio Llombart; Antonio Frassoldati; Outi Paija; Harm Peter Sleeboom; Guy Jerusalem; Jeroen Mebis; Ines Deleu; Joel Miller; Nora Schenk; Patrick Neven

Book ID: 113538950
Publisher: CIG Media Group, LP.
Year: 2012
Tongue: English
Weight: 437 KB
Volume: 12
Category: Article
ISSN: 1526-8209
DOI: 10.1016/j.clbc.2011.08.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effective inhibition of aromatase inhibi

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole : ZO-FAST study results

✍ Nigel J. Bundred; Ian D. Campbell; Neville Davidson; Richard H. DeBoer; Holger E 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

## Abstract ## BACKGROUND. Letrozole is safe and effective in postmenopausal women with estrogen receptor‐positive early breast cancer, but long‐term aromatase inhibitor use may cause bone loss and increase fracture risk. This study evaluated an immediate or delayed strategy of bone protection the

2008 POSTER The E-ZO-FAST trial: Zoledro

2008 POSTER The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let)

✍ N. Schenk; A. Lombart; A. Frassoladti; P. Neven; G. Jerusalem; I. Deleu; J. Mebi 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 84 KB

Zoledronic acid (ZA) prevents aromatase

Zoledronic acid (ZA) prevents aromatase inhibitor (Al)-associated bone loss in postmenopausal women with early breast cancer -36-month follow-up of the Z-FAST study

✍ A. Brufskv; L. Bosserman; R. Caradonna; B. Haley; M. Jones; H. Moore; M. Dong; G 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Zoledronic Acid Effectively Prevents Aro

Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results

✍ Adam M. Brufsky; Linda D. Bosserman; Richard R. Caradonna; Barbara B. Haley; C. 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 151 KB

0132 The effect of zoledronic acid in po

0132 The effect of zoledronic acid in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole: 24 months integrated follow-up of the Z-FAST/ZO-FAST trials

✍ A. Frassoldati; A. Brufsky; N. Bundred; R. Lambert-Falls; P. Hadji; N. Schenk; O 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 62 KB

P153 An integrated analysis of zoledroni

P153 An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)

✍ A. Brufsky; N. Bundred; R. Coleman; R. Lambert-Falls; R. Mena; M. Dong; N. Schen 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 46 KB